Associations - PTCH1 (Patched 1)

PTCH1 mutation	Hormone Receptor Positive Breast Cancer	PTCH1 mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
PTCH1 mutation	Medulloblastoma	PTCH1 mutation	Medulloblastoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Colorectal Cancer	PTCH1 mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PTCH1 mutation	Melanoma	PTCH1 mutation	Melanoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Salivary Gland Cancer	PTCH1 mutation	Salivary Gland Cancer	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH E947T	Soft Tissue Sarcoma	PTCH E947T	Soft Tissue Sarcoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Non Small Cell Lung Cancer	PTCH1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4
PTCH1-GLI1 fusion	Ovarian Cancer	PTCH1-GLI1 fusion	Ovarian Cancer	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
PTCH1-GLI1 fusion	Ovarian Cancer	PTCH1-GLI1 fusion	Ovarian Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
PTCH1 S616G	Basal Cell Carcinoma	PTCH1 S616G	Basal Cell Carcinoma	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4
PTCH1 deletion	Medulloblastoma	PTCH1 deletion	Medulloblastoma	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D	IPI 926 oral Sensitive: D – Preclinical IPI 926 oral Sensitive : D

PTCH1 (Patched 1)

Associations(24)

Associations
(24)